Omeros Corporation $OMER Shares Sold by Newbridge Financial Services Group Inc.

Newbridge Financial Services Group Inc. lowered its stake in shares of Omeros Corporation (NASDAQ:OMER) by 74.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,310 shares of the biopharmaceutical company’s stock after selling 100,200 shares during the quarter. Newbridge Financial Services Group Inc.’s holdings in Omeros were worth $589,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Omeros by 9.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 2,631 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares during the period. Rhumbline Advisers grew its holdings in shares of Omeros by 7.1% during the 3rd quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 7,048 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Omeros by 86.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,929 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 10,161 shares during the period. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in shares of Omeros during the 2nd quarter worth about $32,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Wall Street Zen upgraded Omeros from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research upgraded Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. D. Boral Capital reiterated a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Finally, HC Wainwright boosted their target price on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Insiders Place Their Bets

In other Omeros news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 12.90% of the stock is currently owned by corporate insiders.

Omeros Stock Up 0.8%

NASDAQ OMER opened at $10.98 on Wednesday. The stock has a market cap of $790.56 million, a PE ratio of -21.96 and a beta of 2.53. Omeros Corporation has a fifty-two week low of $2.95 and a fifty-two week high of $17.65. The business has a 50 day moving average price of $11.31 and a two-hundred day moving average price of $10.01.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $3.69. Sell-side analysts anticipate that Omeros Corporation will post -3.09 EPS for the current fiscal year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.